ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 385

Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention

Silvia Rollefstad1, Eirik Ikdahl2, Tore K. Kvien3,4, Terje R. Pedersen4,5, Ingar Holme6 and Anne G. Semb2, 1Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Faculty of Medicine, University of Oslo, Oslo, Norway, 5Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, 6Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Inflammation, Lipids, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV) disease. Our aim was to describe doses of statins needed to obtain recommended lipid goals in patients with inflammatory joint disease (IJD), including RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Further, to evaluate if baseline systemic inflammation and lipid levels were associated with statin dose (conventional vs. intensive) needed to obtain guideline recommended low density lipoprotein cholesterol (LDL-c) goal in patients with IJD.

Methods : CV risk stratification was performed at the first consultation in a preventive cardio-rheuma clinic in 202 patients (RA: n=124, AS: n=52, PsA: n=26). The patients were classified to either primary or secondary CV prevention with lipid lowering (LL) treatment, or to have low risk with no indication for medical intervention. LL treatment was initiated with statins and adjusted until at least two lipid targets were achieved. Any side effects/intolerance was recorded. Intensive LL treatment was defined as rosuvastatin ≥ 20 mg, atorvastatin and simvastatin ≥ 80 mg, and conventional LL treatment was defined as all lower doses.

Results: Type or dosage of statins and number of dose adjustments to obtain lipid goals were similar in patients with RA, AS and PsA. There was equal need for change of statin medication across the 3 IJD’s due to intolerance/adverse event(s). In a univariate analysis neither systemic inflammation (CRP/ESR: p-value 0.10 and 0.11, respectively) nor lipid levels (LDL-c/total cholesterol (TC): p-value 0.17 and 0.34, respectively) at baseline were associated with the dose of statin needed to achieve LDL-c targets (Figure).

Conclusion: Systemic inflammation or lipid levels did not influence statin dose (conventional or intensive) needed to obtain guideline recommended lipid targets in CV prevention. Whether the background inflammation in IJD patients over time influences the CV risk reduction related to statins is yet unknown.

 SHAPE  * MERGEFORMAT

Figure: Doses of lipid lowering treatment (LLT) needed to achieve LDL-c goals

Baseline:

s


Disclosure:

S. Rollefstad,
None;

E. Ikdahl,
None;

T. K. Kvien,
None;

T. R. Pedersen,

Pfizer, Merck-Schering Plough, AstraZeneca,

5;

I. Holme,

Pfizer, Merck/Schering Plough, AstraZeneca, Roche,

5;

A. G. Semb,

Merck/Schering-Plough, Abbott, BMS, Pfizer/Wyeth, Genentech and Roche,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-inflammation-in-patients-with-inflammatory-joint-disease-does-not-influence-statin-dose-needed-to-obtain-low-density-lipoprotein-cholesterol-goal-in-cardiovascular-prevention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology